


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-20.31%
-3.34%
+0.86%
PFE
Pfizer
$25.77
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
PFE Price Performance
$25.17 (+2.38%)
$24.61 (+4.71%)
$24.71 (+4.29%)
$25.56 (+0.82%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
SELL
Date
Action
Rating
Firm
Jan 16, 2026
Initiate
Neutral
UBS
Jan 12, 2026
Initiate
Neutral
UBS
Dec 30, 2025
Reiterate
Buy
Scotiabank
Dec 22, 2025
Downgrade
Hold
Dec 17, 2025
Reiterate
Buy
Guggenheim
NVS
Novartis AG
149.86
-0.78%
NVO
Novo Nordisk A/S
50.30
-14.64%
SNY
Sanofi
47.49
+0.47%
AZN
Astrazeneca
184.32
-2.17%
MRK
Merck Company
115.84
+2.18%
PFE
Pfizer
25.77
-3.34%
C
Citigroup
117.71
+1.27%
RAYA
Erayak Power Solution
1.19
-10.53%
SMTK
SmartKem Inc.
0.58
-16.82%
STM
STMicroelectronics N.V.
27.86
-3.23%
What is PFE current stock price?
What are PFE stock strengths?
What is PFE Risk Level?
What is PFE market cap and volume?
What is PFE current Stock IQ?
Should I buy PFE stock right now?
Is PFE a Strong Buy right now?
What does a 'Strong Buy' rating mean for PFE?
What does a 'Strong Sell' rating mean for PFE?
What factors influence PFE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-20.31%
-3.34%
+0.86%
PFE
Pfizer
Current Price
$25.77
Linked to PFE
NVS
Novartis AG
149.86
-0.78%
NVO
Novo Nordisk A/S
50.30
-14.64%
SNY
Sanofi
47.49
+0.47%
AZN
Astrazeneca
184.32
-2.17%
MRK
Merck Company
115.84
+2.18%
Recently Viewed
IRM
Iron Mountainorporated
88.61
-0.91%
PFE
Pfizer
25.77
-3.34%
C
Citigroup
117.71
+1.27%
RAYA
Erayak Power Solution
1.19
-10.53%
SMTK
SmartKem Inc.
0.58
-16.82%

PFE Price Performance
$25.17 (+2.38%)
$24.61 (+4.71%)
$24.71 (+4.29%)
$25.56 (+0.82%)
PFE Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
SELL
Jan 16, 2026
Initiate
Neutral
UBS
Jan 12, 2026
Initiate
Neutral
UBS
Dec 30, 2025
Reiterate
Buy
Scotiabank
Dec 22, 2025
Downgrade
Hold
Dec 17, 2025
Reiterate
Buy
Guggenheim
PFE Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
PFE Latest Analysis
Pfizer: Messy Q4 Earnings Mask An Improving Business.
Today
Why Pfizer Stock Dropped Today. Key PointsPfizer beat on 2025 sales and beat on earnings -- but still delivered a loss.
Today
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data. PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.
Today
Pfizer Dives. Why Lillys Zepbound Still Looks Like The Weight-Loss Heavyweight. An analyst says Eli Lillys Zepbound still looks like the heavyweight in weight loss compared to Pfizers injection.The post Pfizer Dives. Why Lilly'.s Zepbound Still Looks Like The Weight-Loss Heavyweight appeared first on Investor'.s Business Daily.
Today
Silver Surges Over 15%. Pfizer Earnings Top Views. United States stocks traded lower midway through trading with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49316.23 while the NASDAQ dipped 1.23% to 23302.18. The S&.P 500 also fell dropping 0.62% to 6933.29.Check This Out: Materials shares gained by 1.8% on Tuesday.In trading on Tuesday information technology stocks fell by 1.9%.On Tuesday ) shared topline data from a mid-stage study for a weight loss dru
Today
Pfizer slips as analysts react to underwhelming outlook obesity drug data.
Today
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever.
Today
LGND: New Year Program Updates. By In the wake of the December analyst day Ligand Pharmaceuticals Inc.s (NASDAQ:LGND) partners have seen meaningful activity with another acquisition for Pelthos a delay in Filsparis Target Action Date a drug application acceptance for Ohtuvayre in China positive results for Palvellas portfolio and a strategic collaboration for BOT/ BAL. Ligand also made an investment in Athira (now LeonaBio) as part of a consortium in support of the acquisition of lasofoxifene. I
Today
Pfizer weight-loss drug data raises questions about side effects shares fall.
Today
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates. Pfizer (PFE) delivered earnings and revenue surprises of 16.81% and 4.26% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Today
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.